Vepsitamab
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation[1].
Product Specifications
CAS Number
[2413453-53-7]
Product Name Alternative
AMG 199
UNSPSC
12352203
Target
CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vepsitamab.html
Purity
98.44
Solubility
10 mM in DMSO
Smiles
[Vepsitamab]
Molecular Weight
(105 kDa)
References & Citations
[1]Joseph Chao, et al. Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. 2020 ASCO Annual Meeting I.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
131396-AP 100 µL
PKM2 (PKM, OIP3, PK2, PK3, Pyruvate Kinase Isozymes M1/M2, Cytosolic Thyroid Hormone-binding Protein, Opa-interacting Protein 3, Pyruvate Kinase 2/3, Pyruvate Kinase Muscle Isozyme, Thyroid Hormone-binding Protein 1, Tumor M2-PK, p58, MGC3932, OIP3, PK3, PKM, TCB, THBP1) (AP) discontinued
Ask
View Details